These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 20358202)

  • 41. Autoimmune Pitfalls of Anti-Tumor Necrosis Factor-Alpha Therapy.
    Roginić S; Jelić A; Stipić-Marković A; Marinko A; Artuković IN; Dušanka MK
    Isr Med Assoc J; 2015 Feb; 17(2):117-9. PubMed ID: 26223091
    [No Abstract]   [Full Text] [Related]  

  • 42. Infectious complications in patients with psoriasis and rheumatoid arthritis treated with antitumor necrosis factor agents and methotrexate.
    Darabi K; Jaiswal R; Hostetler S; Bechtel M; Zirwas M
    J Drugs Dermatol; 2009 Feb; 8(2):175-8. PubMed ID: 19213235
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
    Sidiropoulos PI; Boumpas DT
    Ann Rheum Dis; 2006 Jun; 65(6):701-3. PubMed ID: 16699049
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of pseudogout during etanercept treatment.
    Josefina M; Ana CJ; Ariel V; Silvio AA
    J Clin Rheumatol; 2007 Jun; 13(3):177. PubMed ID: 17551392
    [No Abstract]   [Full Text] [Related]  

  • 45. Neutropenia after the third cycle of etanercept: could it be due to immunogenicity?
    Olsen NJ; Elmagboul N
    J Clin Rheumatol; 2014 Jun; 20(4):237-8. PubMed ID: 24847756
    [No Abstract]   [Full Text] [Related]  

  • 46. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients.
    Verschueren K; Van Essche E; Verschueren P; Taelman V; Westhovens R
    Clin Rheumatol; 2007 Nov; 26(11):1969-71. PubMed ID: 17340045
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Surgery during etanercept therapy in patients with rheumatoid arthritis: is it time to follow patient preferences?
    Corrao S; Pistone G; Arnone S; Calvo L; Scaglione R; Licata G
    Intern Emerg Med; 2008 Mar; 3(1):73-5. PubMed ID: 18270790
    [No Abstract]   [Full Text] [Related]  

  • 48. COMET's path, and the new biologicals in rheumatoid arthritis.
    Kremer JM
    Lancet; 2008 Aug; 372(9636):347-8. PubMed ID: 18635257
    [No Abstract]   [Full Text] [Related]  

  • 49. Acute ocular myositis occurring under etanercept for rheumatoid arthritis.
    Couderc M; Mathieu S; Tournadre A; Dubost JJ; Soubrier M
    Joint Bone Spine; 2014 Oct; 81(5):445-6. PubMed ID: 24746476
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Echinococcus multilocularis infection and TNF inhibitor treatment in a patient with rheumatoid arthritis.
    Weiner SM; Krenn V; Koelbel C; Hoffmann HG; Hinkeldey K; Ockert D
    Rheumatol Int; 2011 Oct; 31(10):1399-400. PubMed ID: 20676647
    [No Abstract]   [Full Text] [Related]  

  • 51. Paradoxical psoriatic arthritis in a patient with rheumatoid arthritis treated by TNFα blocker.
    Villani AP; Weiler L; Jullien D; Chapurlat R; Confavreux C
    Joint Bone Spine; 2014 Oct; 81(5):455-6. PubMed ID: 24561024
    [No Abstract]   [Full Text] [Related]  

  • 52. Development of recurrent pseudoseptic arthritis in a patient with rheumatoid arthritis receiving TNF-alpha blocker.
    Korkmaz C; Kaşifoğlu T
    Joint Bone Spine; 2006 Dec; 73(6):767-8. PubMed ID: 17126056
    [No Abstract]   [Full Text] [Related]  

  • 53. Delayed spinal infection after laminectomy in a patient with rheumatoid arthritis interruptedly exposed to anti-tumor necrosis factor alpha agents.
    Mori S; Tomita Y; Horikawa T; Cho I; Sugimoto M
    Clin Rheumatol; 2008 Jul; 27(7):937-9. PubMed ID: 18330608
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Viral pneumonia as a serious complication of etanercept therapy.
    Smith D; Letendre S
    Ann Intern Med; 2002 Jan; 136(2):174. PubMed ID: 11790076
    [No Abstract]   [Full Text] [Related]  

  • 55. Occurrence of vesicocolic fistula with a use of etanercept: a cautionary tale.
    Ganeshan A; Quen L; Smith D
    J Clin Rheumatol; 2005 Oct; 11(5):290-1. PubMed ID: 16357782
    [No Abstract]   [Full Text] [Related]  

  • 56. [Adverse events in rheumatoid arthritis patient with etanercept therapy: the appearance of osteomalacia].
    D'Amore M; Minenna G; D'Amore S
    Recenti Prog Med; 2005 Nov; 96(11):552-5. PubMed ID: 16499162
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Creutzfeldt-Jakob disease in a patient treated by etanercept for rheumatoid arthritis (RA): just a coincidence?
    Soubrier M; Haïk S; Hauw JJ; Corvol JC; Lyon-Caen O; Dougados M
    Joint Bone Spine; 2010 Mar; 77(2):174-5. PubMed ID: 20097590
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of the efficacy and safety of etanercept 50 mg once weekly in Japanese patients with rheumatoid arthritis and comparison with 25 mg etanercept twice weekly.
    Mochizuki T; Momohara S; Yano K; Shirahata T; Ikari K
    Mod Rheumatol; 2013 Sep; 23(5):994-1000. PubMed ID: 23138447
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose.
    Raffeiner B; Botsios C; Ometto F; Bernardi L; Stramare R; Todesco S; Sfriso P; Punzi L
    Clin Exp Rheumatol; 2015; 33(1):63-8. PubMed ID: 25535985
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dose reduction of etanercept--can we treat more patients using a fixed budget?
    Clunie G; Voules S; Watts R
    Rheumatology (Oxford); 2003 Apr; 42(4):600-1. PubMed ID: 12649411
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.